The FDA's expanded indication for the Dexcom G5 Continuous Glucose Monitoring System allows for replacement of fingerstick glucose testing.
The system allows patients and their caregivers to access glucose measurements through their pump or through a mobile app.
The Contour®Next One Blood Glucose Management System will be available in early 2017.
An implantable continuous glucose monitor appears to be a safe and effective alternative to a transcutaneous monitor in diabetes.
FDA approval of the first closed-loop insulin delivery system is exciting for both physicians and patients. What does this mean for the future?
Approval was based on a clinical trial that included 123 people with type 1 diabetes who used the MiniMed 670G hybrid closed-loop system for 3 months, after a 2-week period of no use.
The FDA is coordinating with investigators, manufacturers, clinicians, and others to bring automated insulin delivery devices to market.
The system was feasible, safe, and effective for managing hyperglycemia in this patient population.
Artificial pancreas was linked to 3-fold reduction of time-in-hypoglycemia for 5- to 9-year-olds.
Overnight-only and 24/7 closed-loop control reduced hypoglycemia and increased time in range.